Effect of nonviable preparations from human immunodeficiency virus type 1 on nuclear matrix-associated DNA polymerase alpha and DNA topoisomerase II activities. 1990

W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
Abteilung Angewandte Molekularbiologie, Universität, Mainz, F.R.G.

In a previous paper, we determined that treatment of lymphocytes with nonviable preparations of human immunodeficiency virus type 1 (HIV-1) results in an impairment of the phosphatidylinositol/protein kinase C pathway, most likely due to an inhibition of the cleavage of phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol, mediated by phospholipase C. Here we show that one consequence of these changes is a reduced phosphorylation of nuclear matrix-associated DNA topoisomerase II, resulting in an inhibition of the activity of this enzyme. Antibodies to the viral proteins suppressed the inhibitory effects caused by the HIV-1 preparation. Furthermore, the phytohemagglutinin A-caused augmentation of nuclear matrix-associated DNA polymerase alpha and beta activities was found to be abolished by coincubation with the HIV preparation or with the HIV-1 gp120. The phytohemagglutinin A-enhanced matrix association and processivity of DNA polymerase alpha was determined to be reduced if the lymphocytes were in contact with HIV-1 preparation. These results suggest that the reduced proliferative response of lymphocytes to phytohemagglutinin A in the presence of disrupted HIV-1 preparation is due to inhibition of at least two, perhaps separate, pathways, one involving protein kinase C resulting in a reduced phosphorylation of DNA topoisomerase II and the other changing the state of matrix association of DNA polymerase alpha and beta.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004257 DNA Polymerase II A DNA-dependent DNA polymerase characterized in E. coli and other lower organisms. It may be present in higher organisms and has an intrinsic molecular activity only 5% of that of DNA Polymerase I. This polymerase has 3'-5' exonuclease activity, is effective only on duplex DNA with gaps or single-strand ends of less than 100 nucleotides as template, and is inhibited by sulfhydryl reagents. DNA Polymerase epsilon,DNA-Dependent DNA Polymerase II,DNA Pol II,DNA Dependent DNA Polymerase II
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015530 Nuclear Matrix The residual framework structure of the CELL NUCLEUS that maintains many of the overall architectural features of the cell nucleus including the nuclear lamina with NUCLEAR PORE complex structures, residual CELL NUCLEOLI and an extensive fibrogranular structure in the nuclear interior. (Advan. Enzyme Regul. 2002; 42:39-52) Nuclear Scaffold,Nucleoskeleton,Matrices, Nuclear,Matrix, Nuclear,Nuclear Matrices,Nuclear Scaffolds,Nucleoskeletons,Scaffold, Nuclear,Scaffolds, Nuclear
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
August 1989, European journal of biochemistry,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
June 1997, International journal of oncology,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
February 2005, The Pediatric infectious disease journal,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
September 1982, Nucleic acids research,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
August 1995, The Pediatric infectious disease journal,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
January 1988, Doklady Akademii nauk SSSR,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
January 2004, Biochemical and biophysical research communications,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
October 1997, Molecular and cellular biology,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
January 1996, Proceedings of the National Academy of Sciences of the United States of America,
W E Müller, and E Matthes, and P Reuter, and R Wenger, and K Friese, and Y Kuchino, and H C Schröder
January 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Copied contents to your clipboard!